// App-Quantinova.ai

3071 : Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

Researchers

Presenter

  • Luis A. Diaz

Principal Investigators

  • Jean-Pierre Delord

  • Ronnie Shapira-Frommer

  • Ravit Geva

  • Nir Peled

  • Tae Won Kim

  • Thierry Andre

  • Eric Van Cutsem

  • Rosine Guimbaud

  • Dirk Jaeger

  • Elena Elez

  • Takayuki Yoshino

  • Andrew K. Joe

  • Baohoang Lam

  • Christine K. Gause

  • Scott Knowles Pruitt

  • S. Peter Kang

  • Dung T Le

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France

  • Sheba Medical Center, Ramat-Gan, Ireland

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Davidoff Cancer Center, Petach Tiqwa, Israel

  • Medical Oncology Department, Saint-Antoine Hospital, Paris, France

  • University Hospital of Rangueil, Toulouse, France

  • Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, Japan

  • Merck & Co., Inc., Kenilworth, NJ

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

Locations

  • Japan

  • Germany

  • Spain

  • United States

  • Israel

  • France

  • Belgium

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Microsatellite instability-high

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02628067

  • NCT02460198

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved